​

Soleno Therapeutics (SLNO) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

SLNO Stock Forecast

Soleno Therapeutics (SLNO) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $89.50, with a high of $105.00 and a low of $70.00. This represents a 27.89% increase from the last price of $69.98.

- $30 $60 $90 $120 $150 High: $105 Avg: $89.5 Low: $70 Last Closed Price: $69.98

SLNO Stock Rating

Soleno Therapeutics stock's rating consensus is Buy, based on 9 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 9 0 9 Strong Sell Sell Hold Buy Strong Buy

SLNO Price Target Upside V Benchmarks

TypeNameUpside
StockSoleno Therapeutics27.89%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts339
Avg Price Target$96.00$96.00$80.11
Last Closing Price$69.98$69.98$69.98
Upside/Downside37.18%37.18%14.48%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2535---8
Mar, 2534---7
Feb, 2534---7
Jan, 2535---8
Dec, 2435---8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 28, 2025Debjit ChattopadhyayGuggenheim$81.00$70.2215.35%15.75%
Dec 02, 2024Raghuram SelvarajuH.C. Wainwright$70.00$50.9137.50%0.03%
Oct 01, 2024Dae Gon HaStifel Nicolaus$74.00$50.4946.56%5.74%
Aug 27, 2024Dae GonStifel Nicolaus$59.00$49.0420.31%-15.69%
Aug 27, 2024Leland GershellOppenheimer$65.00$46.7639.01%-7.12%
May 23, 2024Yasmeen RahimiPiper Sandler$93.00$42.42119.24%32.90%
May 09, 2024Brian SkorneyRobert W. Baird$72.00$47.6451.13%2.89%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 28, 2025GuggenheimBuyBuyhold
Mar 27, 2025LaidlawBuyBuyhold
Dec 02, 2024H.C. WainwrightBuyBuyhold
Sep 27, 2024Piper SandlerOverweightOverweighthold
Sep 03, 2024H.C. WainwrightBuyinitialise
Aug 12, 2024OppenheimerOutperformOutperformhold
May 23, 2024Piper SandlerOverweightOverweighthold
Sep 15, 2023OppenheimerOutperformOutperformhold
Jul 11, 2023Cantor FitzgeraldOverweightinitialise
Apr 05, 2022OppenheimerOutperformOutperformhold

Financial Forecast

EPS Forecast

$-5 $-1 $3 $7 $11 $15 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.36$-4.38----
Avg Forecast$-2.47$-4.22$-2.60$-0.77$2.68$5.91
High Forecast$-2.32$-4.14$-2.05$0.89$4.36$12.24
Low Forecast$-2.86$-4.29$-3.30$-3.00$-1.48$-0.02
Surprise %-4.45%3.79%----

Revenue Forecast

$0 $200M $400M $600M $800M $1B Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast-$5.63M$37.02M$158.76M$336.47M$535.04M
High Forecast-$10.26M$77.63M$289.45M$613.47M$975.51M
Low Forecast-$1.29M$10.84M$36.30M$76.94M$122.34M
Surprise %------

Net Income Forecast

$-200M $-110M $-20M $70M $160M $250M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-38.99M$-175.85M----
Avg Forecast$-38.99M$-69.56M$-44.12M$-28.80M$23.75M$97.47M
High Forecast$-38.18M$-68.34M$-33.84M$14.68M$71.91M$201.78M
Low Forecast$-47.13M$-70.78M$-54.40M$-49.48M$-24.41M$-267.86K
Surprise %-152.81%----

SLNO Forecast FAQ

Is Soleno Therapeutics stock a buy?

Soleno Therapeutics stock has a consensus rating of Buy, based on 9 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Soleno Therapeutics is a favorable investment for most analysts.

What is Soleno Therapeutics's price target?

Soleno Therapeutics's price target, set by 9 Wall Street analysts, averages $89.5 over the next 12 months. The price target range spans from $70 at the low end to $105 at the high end, suggesting a potential 27.89% change from the previous closing price of $69.98.

How does Soleno Therapeutics stock forecast compare to its benchmarks?

Soleno Therapeutics's stock forecast shows a 27.89% upside, underperforming the average forecast for the healthcare stocks sector (35.25%) and underperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Soleno Therapeutics over the past three months?

  • April 2025: 37.50% Strong Buy, 62.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 42.86% Strong Buy, 57.14% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 42.86% Strong Buy, 57.14% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Soleno Therapeutics’s EPS forecast?

Soleno Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.6, marking a -40.64% decrease from the reported $-4.38 in 2024. Estimates for the following years are $-0.77 in 2026, $2.68 in 2027, and $5.91 in 2028.

What is Soleno Therapeutics’s revenue forecast?

Soleno Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $37.02M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $158.76M, followed by $336.47M for 2027, and $535.04M for 2028.

What is Soleno Therapeutics’s net income forecast?

Soleno Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-44.12M, representing a -74.91% decrease from the reported $-176M in 2024. Projections indicate $-28.801M in 2026, $23.75M in 2027, and $97.47M in 2028.